Arcadia Biosciences (RKDA) Cost of Revenue (2014 - 2026)

Arcadia Biosciences (RKDA) has 12 years of Cost of Revenue data on file, last reported at $709000.0 in Q4 2025.

• Quarterly Cost of Revenue fell 14.27% year-over-year to $709000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.1 million (up 4.59% YoY) and the FY2025 annual result came in at $3.1 million, up 4.56% from the prior year.
• Cost of Revenue retreated to $709000.0 in Q4 2025, from $884000.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $3.8 million in Q4 2021 to a low of $178000.0 in Q4 2023.
• A 5-year average of $1.3 million and a median of $841500.0 in 2021 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2021 — Cost of Revenue soared 548.48% — and 2023, when it tumbled 81.14%.
• Tracing RKDA's Cost of Revenue over 5 years: stood at $3.8 million in 2021, then sank by 76.03% to $900000.0 in 2022, then sank by 80.22% to $178000.0 in 2023, then surged by 364.61% to $827000.0 in 2024, then dropped by 14.27% to $709000.0 in 2025.
• The last three Cost of Revenue figures came in at $709000.0 (Q4 2025), $884000.0 (Q3 2025), and $824000.0 (Q2 2025), per Business Quant data.